Gastrointestinal Cancers: Managed Care Strategies to Improve Resource Utilization With Immune Checkpoint Inhibitors
Monday, Nov. 9, 2020, 7-8:30pm ET
Provided by Pharmacy Times Continuing Education.
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Continuing education credit available for pharmacists.
The treatment of gastrointestinal (GI) cancers is rapidly evolving. Immune checkpoint inhibitors are emerging therapies for these cancers, which encompass esophageal, gastric, colorectal, hepatocellular, anal, and pancreatic cancers. As pivotal members of the team caring for patients with GI cancers, managed care pharmacists should have knowledge of the unique adverse effects associated with use of immune checkpoint inhibitors. To ensure appropriate utilization of immune checkpoint inhibitors and optimal therapy selection, managed care professionals must be familiar with the place in therapy of checkpoint inhibitors and develop cost-effective strategies for the management of patients with GI cancers utilizing these agents.
Pharmacy Times Continuing Education